665-P: Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs. 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses

Once-weekly subcutaneous semaglutide 2.0 mg showed superior efficacy with similar safety vs. 1.0 mg in 961 participants with type 2 diabetes (HbA1c 8.0-10.0%) after 40 weeks in SUSTAIN FORTE. We assessed the effect of semaglutide 2.0 mg vs. 1.0 mg on HbA1c and body weight (BW) in prespecified baseli...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2021-06, Vol.70 (Supplement_1)
Hauptverfasser:	BUSE, JOHN B., AUERBACH, PERNILLE, BAJAJ, HARPREET S., FUKUSHIMA, YASUSHI, LINGVAY, ILDIKO, MACURA, STANISLAVA, SØNDERGAARD, ANETTE L., TANKOVA, TSVETALINA, TENTOLOURIS, NIKOLAOS, FRIAS, JUAN P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antidiabetics Body weight Diabetes Diabetes mellitus (non-insulin dependent) Glucose Hemoglobin Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Once-weekly subcutaneous semaglutide 2.0 mg showed superior efficacy with similar safety vs. 1.0 mg in 961 participants with type 2 diabetes (HbA1c 8.0-10.0%) after 40 weeks in SUSTAIN FORTE. We assessed the effect of semaglutide 2.0 mg vs. 1.0 mg on HbA1c and body weight (BW) in prespecified baseline (BL) HbA1c (
ISSN:	0012-1797 1939-327X
DOI:	10.2337/db21-665-P